As of 2026-04-08, the Relative Valuation of Protagonist Therapeutics Inc (PTGX) is (46.10) USD. This relative valuation is based on P/E multiples. With the latest stock price at 103.75 USD, the upside of Protagonist Therapeutics Inc based on Relative Valuation is -144.4%.
The range of the Relative Valuation is (44.14) - (50.26) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.6x - 26.2x | 23.8x |
| Forward P/E multiples | 21.0x - 24.6x | 21.4x |
| Fair Price | (44.14) - (50.26) | (46.10) |
| Upside | -142.5% - -148.4% | -144.4% |
| Date | P/E |
| 2026-04-06 | -50.45 |
| 2026-04-02 | -50.88 |
| 2026-04-01 | -50.83 |
| 2026-03-31 | -51.68 |
| 2026-03-30 | -48.96 |
| 2026-03-27 | -48.52 |
| 2026-03-26 | -50.09 |
| 2026-03-25 | -51.14 |
| 2026-03-24 | -49.22 |
| 2026-03-23 | -48.31 |
| 2026-03-20 | -48.47 |
| 2026-03-19 | -49.85 |
| 2026-03-18 | -47.60 |
| 2026-03-17 | -47.67 |
| 2026-03-16 | -47.43 |
| 2026-03-13 | -45.28 |
| 2026-03-12 | -46.78 |
| 2026-03-11 | -47.30 |
| 2026-03-10 | -47.58 |
| 2026-03-09 | -47.39 |
| 2026-03-06 | -45.15 |
| 2026-03-05 | -44.82 |
| 2026-03-04 | -46.49 |
| 2026-03-03 | -44.76 |
| 2026-03-02 | -46.20 |
| 2026-02-27 | -45.15 |
| 2026-02-26 | -43.34 |
| 2026-02-25 | -42.70 |
| 2026-02-24 | -42.85 |
| 2026-02-23 | -42.45 |
| 2026-02-20 | -40.58 |
| 2026-02-19 | -40.74 |
| 2026-02-18 | -40.69 |
| 2026-02-17 | -40.43 |
| 2026-02-13 | -39.95 |
| 2026-02-12 | -40.17 |
| 2026-02-11 | -40.93 |
| 2026-02-10 | -41.13 |
| 2026-02-09 | -40.85 |
| 2026-02-06 | -41.42 |
| 2026-02-05 | -39.55 |
| 2026-02-04 | -40.84 |
| 2026-02-03 | -41.96 |
| 2026-02-02 | -40.72 |
| 2026-01-30 | -40.11 |
| 2026-01-29 | -39.09 |
| 2026-01-28 | -40.09 |
| 2026-01-27 | -40.73 |
| 2026-01-26 | -40.35 |
| 2026-01-23 | -40.74 |